Answers are grounded in this paper and cite their sources.
Background Sarcomas are mesenchymal malignancies with marked inter- and intra-subtype heterogeneity. Responses to immune checkpoint inhibitors (ICIs) remain limited outside a few histologies. While total tumor-infiltrating lymphocyte (TIL) counts and peripheral blood ratios have been studied, the functional heterogeneity of CD4 + and CD8 + T lymphocyte subsets across sarcoma subtypes has not, to our knowledge, been systematically compared. Objective To systematically review the distribution, prognostic value, and therapeutic vulnerabilities of CD4 + (Th1/Th2/Th17/Tfh/Treg) and CD8 + (cytotoxic/exhausted/memory/tissue-resident) functional subsets across sarcoma subtypes, and to identify druggable targets from subset-specific biology. Methods Systematic review per PRISMA 2020 and SWiM guidelines. PubMed, Embase, Web of Science, and Cochrane Library were searched from 1 January 2000 to 31 August 2026 for studies reporting quantitative CD4 + or CD8 + functional subset data in histologically confirmed human sarcoma. Risk of bias was assessed with NOS and QUADAS-2. Evidence was synthesized narratively using SWiM with vote counting by outcome direction. Results 99 studies comprising 9,983 patients (not de-duplicated) across thirteen sarcoma subtype groupings were included, spanning IHC, multiplex IF, flow cytometry, scRNA-seq, and bulk transcriptomic deconvolution. CD8 + cytotoxicity was consistently associated with favorable prognosis in osteosarcoma and UPS, whereas deep exhaustion (PD-1 + TIM-3 + LAG-3 + ) characterized LMS and DDLPS; shallow CD8 + exhaustion marked ICI-responsive subtypes. Direct, marker-validated reporting of functional CD4 + helper subsets (Th1, Th17, Tfh) was sparse and assay-dependent, precluding cross-study synthesis, whereas high Treg density was generally adverse. TLS enrichment in DDLPS, UPS, and SS was associated with improved survival and ICI benefit. Among the 59 studies with an unambiguous direction, 47.5% reported a favorable direction (95% CI 35.3-60.0%), providing no evidence of an overall directional tendency. Conclusions CD8 + T cell functional state—rather than CD4 + helper polarization—is the best-resolved determinant of prognosis and ICI sensitivity across sarcoma subtypes, with shallow exhaustion and TLS marking responsive tumors; the relative scarcity of functional CD4 + subset data is itself a key finding. These patterns support subtype-specific profiling for immunotherapy trial stratification, but prospective validation of incremental predictive value over existing approaches is required. Systematic review registration https://www.crd.york.ac.uk/prospero/ , Identifier CRD420261443233.
No takes yet. Share an insight, caveat, or question.
Xiao et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: